11 November 2026

ECO Animal Health Group plc

(“ECO” or the “Company”)

Submission of EU marketing authorisation application for ECOVAXXIN® MG

ECO Animal Health Group plc (AIM: EAH), a leading global animal health company developing and marketing branded veterinary products to improve livestock productivity and welfare, announces that it has submitted a Marketing Authorisation Application and supporting dossier to the European Medicines Agency (“EMA”) for ECOVAXXIN® MG, its live poultry vaccine targeting Mycoplasma gallisepticum.

ECOVAXXIN® MG is the second vaccine product from ECO’s proprietary R&D pipeline to be submitted for marketing authorisation to the EMA. It follows ECOVAXXIN® MS, the Company’s poultry vaccine against Mycoplasma synoviae, which was commercially launched in the EU in July 2026. If approved, ECOVAXXIN® MG will extend ECO’s poultry vaccine offering across major Mycoplasma infections and will sit alongside Aivlosin®, the Company’s market leading antibiotic for the treatment of respiratory and intestinal diseases in pigs and poultry.

In March 2026, ECOVAXXIN® MG received a favourable safety assessment from the United States Department of Agriculture, marking an important step towards achieving marketing authorisation for the vaccine in the United States.

David Hallas, Chief Executive Officer of ECO Animal Health, said: “The submission of the EU dossier for ECOVAXXIN® MG is an important milestone for ECO and reflects the hard work and commitment of our R&D and regulatory teams. Following the EU approval and launch of ECOVAXXIN® MS, ECOVAXXIN® MG builds on our position in the prevention and treatment of Mycoplasma infection in poultry. Our regulatory plan remains in-line with expectations and we look forward to progressing through the EMA review process and advancing towards a planned launch, while in parallel continuing our work towards US marketing authorisation.”

Mycoplasma gallisepticum is a bacterial pathogen responsible for chronic respiratory disease in chickens which causes decreased egg production leading to major economic losses in poultry. The live strain of the bacteria used for ECOVAXXIN® MG is a naturally attenuated isolate shown to be safe for young chicks.

-Ends-

Contacts

About ECO Animal Health

ECO Animal Health (AIM: EAH) is a leading global animal health company, developing and marketing branded veterinary products that optimise livestock wellbeing and productivity.

The Group’s proprietary lead product, Aivlosin® is a market leading antibiotic for the treatment of respiratory and intestinal diseases in pigs and poultry, distributed to over 70 markets through an established commercial platform.

ECO Animal Health is also investing in the next generation of animal health products through a self-funded R&D pipeline, with a particular focus on prevention and vaccines. The first product from ECO’s pipeline, ECOVAXXIN® MS, a poultry vaccine targeting Mycoplasma synoviae infection, was commercially launched in the EU in July 2026.

Headquartered in the UK, with a global presence, ECO Animal Health employs over 200 people worldwide.

View the Group’s website or LinkedIn page for further information.